Abstract: The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.
Type:
Grant
Filed:
November 10, 2016
Date of Patent:
April 25, 2023
Assignee:
Paracrine Therapeutics AB
Inventors:
Ulf Eriksson, Kristian Pietras, Pernilla Roswall
Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.
Type:
Application
Filed:
May 9, 2022
Publication date:
September 1, 2022
Applicant:
Paracrine Therapeutics AB
Inventors:
Ulf Eriksson, Hong Li, Andrew Scott, Laura Allan
Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.
Type:
Grant
Filed:
June 30, 2017
Date of Patent:
June 7, 2022
Assignee:
PARACRINE THERAPEUTICS AB
Inventors:
Ulf Eriksson, Hong Li, Andrew Scott, Laura Allan
Abstract: The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.
Type:
Application
Filed:
November 10, 2016
Publication date:
June 24, 2021
Applicant:
Paracrine Therapeutics AB
Inventors:
Ulf Eriksson, Kristian Pietras, Pernilla Roswall